Methods of manufacturing adeno-associated viral vectors

By culturing cells with IFNP inhibitors during rAAV vector production, the method addresses the challenges of IFN signaling, enhancing production efficiency and scalability for therapeutic rAAV vectors.

WO2024238399A1PCT designated stage expired Publication Date: 2024-11-21SIREN BIOTECHNOLOGY INC

Patent Information

Application Number
PCT/US2024/028967
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-12
Filing Date
2024-05-10
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current methods for manufacturing recombinant adeno-associated virus (rAAV) vectors face challenges due to activation of stress response pathways like IFN signaling, which affects scalability and production efficiency, particularly when producing therapeutic genes such as interferons.

Method used

The method involves providing cells with a transfer plasmid, AAV Rep and AAV Cap plasmids, and helper nucleic acids, while culturing them in a growth medium containing IFNP inhibitors or inhibitors of IFNP signaling, such as siRNA, small molecules, or natural products, to suppress IFN signaling and enhance rAAV vector production.

Benefits of technology

This approach improves the efficiency and scalability of rAAV vector production by reducing cytotoxicity and increasing yields, making it suitable for therapeutic applications by effectively managing IFN signaling pathways.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 000001
    Figure 000001
  • Figure 000002
    Figure 000002
  • Figure 000003
    Figure 000003
Patent Text Reader

Abstract

Described herein are methods of manufacturing recombinant viral vectors for the treatment of diseases that use inhibitors of interferon beta or inhibitors of interferon signaling in a growth medium comprising an interferon beta inhibitor or using interferon knockdown or knockout cells.
Need to check novelty before this filing date? Find Prior Art

Description

METHODS OF MANUFACTURING ADENO-ASSOCIATED VIRAL VECTORSCROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of and priority to U.S. Provisional Application No. 63 / 501,996 filed May 12, 2023, the entire disclosure of which is hereby incorporated by reference in its entirety for all purposes.SUMMARY OF THE DISCLOSURE

[0002] Described herein, in certain embodiments, are methods for manufacturing a recombinant adeno-associated virus (rAAV) vector comprising a payload of interest, the method comprising: a) providing cells with i) a transfer plasmid comprising the payload of interest; ii) a AAV Rep and AAV Cap plasmid; and iii) one or more helper nucleic acids selected from the group consisting of: Adenovirus E2, Adenovirus E4, and Adenovirus VA; and b) culturing the cells of step a) in a growth medium comprising an IFNP inhibitor or inhibitor of IFNP signaling such that the rAAV vector comprising the payload of interest is produced in the cells.

[0003] In some embodiments, step a) comprises transfecting the cells with the transfer plasmid, the AAV Rep and AAV Cap plasmid, and / or the one or more helper nucleic acids.

[0004] In some embodiments, step a) comprises transducing or infecting the cells with the transfer plasmid, the AAV Rep and AAV Cap plasmid, and / or the one or more helper nucleic acids.

[0005] In some embodiments, the IFNP inhibitor is a nucleic acid molecule, small molecule, IFNP antibody, or natural product.

[0006] In some embodiments, the nucleic acid molecule is selected from the group consisting of: IFNP short interfering RNA (siRNA), IFNP microRNA (miRNA), IFNP short hairpin RNA (shRNA), IFNP antisense oligonucleotide, STAT siRNA, STAT miRNA, STAT shRNA, and STAT antisense oligonucleotide.

[0007] In some embodiments, the small molecule is selected from the group consisting of: carbonyl cyanide m-chlorophenyl hydrazone (CCCP), BX795, ruxolitinib, morphine, dilaudid, methadone, MRT68844, MRT67307, Cyt387, and AZD1480.

[0008] In some embodiments, the IFNP antibody is anifrolumab.

[0009] In some embodiments, the natural product is selected from the group consisting of: emodin, aloin, capsaicin, avicin D, celastrol, withaferin A, thymoquine, caffeic acid, vinorelbine, paclitaxel, evodiamine, cryptotanshinone, honokiol, berbamine, cinnamon bark or a small molecule therein, indirubin, curcumin, FLLL11, FLLL12, FLLL2, FLLL62, resveratrol (SRT501), LTR71, piceatannol, dihydroxystilbene, tetrahydroxystilbene, hexahydroxystilbene,2- bromo-resveratrol and 2-chloro-resveratrol, an oleanolic acid, bardoxolone, an oleanolic derivative, a 3, 5 -di substituted isoxazoles derivative, an acyloxyimino derivative, a 3-acetylated derivative, acetate, an ester derivative, an oximes derivative, catechin, artemisinin, paramyxovirus V protein, Yaba-like disease virus Y136 protein, vaccinia virus B18 protein, Epstein-Barr virus BGLF2 protein, dengue virus NS2A protein, dengue virus NS4A protein, and dengue virus NS4B protein.

[0010] In some embodiments, the inhibitor of IFNP signaling is a JAK inhibitor.

[0011] In some embodiments, the JAK inhibitor is a small molecule inhibitor.

[0012] In some embodiments, the JAK inhibitor is selected from the group consisting of: tofacitinib (CP690, 550 or Xeljanz), baricitinib, ruxolitinib (INCB018424 or INC424), oclacitinib, fdgotinib (jyseleca), upadacitinib (ABT-494), abrocitinib (PF-04965842), itacitinib (INCB039110), fedrantinib, pacritinib, gandotinib (LY2784544), decernotinib, peficitinib (Smyraf, ASP015K, or JNJ-54781532), momelotinib (CYT387), gusacitinib (ASN002), delgocitinib (JTE-052), cerdulatinib (PRT062070), deucravacitinib, lestauritinib, brepocitinib (PF-06700841), ivarmacitinib (SHR0302), and OST-122.

[0013] In some embodiments, the inhibitor of IFNP signaling is a STAT inhibitor.

[0014] In some embodiments, the STAT inhibitor is a small molecule inhibitor, peptide inhibitor, or peptidomimetic inhibitor.

[0015] In some embodiments, the STAT inhibitor is selected from the group consisting of: stattic (STAT Three Inhibitory Compound), STA-21 (NSC628869), LLL-3, LLL12, XZH-5, OPB- 31121, S3I-201, inS3-54A18, STAT3-IN-1, morusin, niclosamide (BAY2353), SH-4-54, WP1066, S3I-201.1066, S3I-1757, STX-0119, BP-1-102, OPB-11077, napabucasin (BBI608), pyrimethamine (GLG-801), TTI-101 (Cl 88-9), nitazoxanide, BP-5-087, pravastatin, pimozide, STAT5-IN-1, AS1517499, BP-1108, BP-1075, stafia-1, leflunomide, niflumic acid, PY*LKTK (Y = phosphotyrosine), PY*LKTK and its tripeptides PY*L and AY*L, ISS610, S31-M2001, ISS840, PM-73G, CJ1383, and rPP-C8.

[0016] In some embodiments, step b) comprises culturing the cells in a suspension culture.

[0017] In some embodiments, step b) comprises culturing the cells in an adherent culture.

[0018] In some embodiments, the cells are stable cell lines.

[0019] In some embodiments, the cells are selected from the group consisting of: A549, HEK- 293, HEK-293T, BHK, CHO, HeLa, MRC5, Sf9, Cos-1, Cos-7, Vero, BSC 1, BSC 40, BMT 10, WI38, HeLa, Saos, C2C12, L cell, HT1080, HepG2, Huh7, K562, primary cells, and a derivative thereof.

[0020] In some embodiments, the payload of interest is an interferon (IFN).

[0021] In some embodiments, the interferon is IFN alpha (IFNa), IFN beta (IFNP), IFN gamma (fFNy), IFN epsilon (IFNs), IFN kappa (IFNK), IFN omega (IFNco), IFN lambda (IFN ), or variants or derivatives thereof.

[0022] In some embodiments, the interferon is IFNp.

[0023] In some embodiments, a serotype of the AAV Rep and AAV Cap plasmid is derived from the group consisting of: AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV 10, AAV11, AAV 12, AAV13, AAV 14, AAV 15, AAV 16, AAV-rh8, AAV-rhlO, AAV- rh20, AAV-rh39, AAV-rh74, AAV-rhM4-l, AAV-hu37, AAV-Anc80, AAV-Anc80L65, AAV- 7m8, AAV-PHP-B, AAV-PHP-EB, AAV-2.5, AAV-2tYF, AAV-3B, AAV-LK03, AAV-HSC1, AAV-HSC2, AAV-HSC3, AAV-HSC4, AAV-HSC5, AAV-HSC6, AAV-HSC7, AAV-HSC8, AAV-HSC9, AAV-HSC10, AAV-HSC11, AAV-HSC12, AAV-HSC13, AAV-HSC14, AAV- HSC15, AAV-TT, AAV-DJ / 8, AAV-Myo, AAV-NP40, AAV-NP59, AAV-NP22, AAV-NP66, AAV-HSC16, and a derivative thereof.

[0024] Described herein, in certain embodiments, are methods for manufacturing a recombinant adeno-associated virus AAV (rAAV) vector, comprising the payload of interest, the method comprising: a) providing IFNP knockdown cells with i) a transfer plasmid comprising the payload of interest; ii) a AAV Rep and AAV Cap plasmid; and iii) one or more helper nucleic acids selected from the group consisting of: Adenovirus E2, Adenovirus E4, and Adenovirus VA; and b) culturing the cells such that the rAAV vector comprising the payload of interest is produced in the cells.

[0025] In some embodiments, step a) comprises transfecting the cells with the transfer plasmid, the AAV Rep and AAV Cap plasmid, and / or the one or more helper nucleic acids.

[0026] In some embodiments, step a) comprises transducing or infecting the cells with the transfer plasmid, the AAV Rep and AAV Cap plasmid, and / or the one or more helper nucleic acids.

[0027] In some embodiments, step b) comprises culturing the cells in a suspension culture.

[0028] In some embodiments, step b) comprises culturing the cells in an adherent culture.

[0029] In some embodiments, the cells are from a stable cell line.

[0030] In some embodiments, the cells are selected from the group consisting of: A549, HEK- 293, HEK-293T, BHK, CHO, HeLa, MRC5, SfP, Cos-1, Cos-7, Vero, BSC 1, BSC 40, BMT 10, WI38, HeLa, Saos, C2C12, L cell, HT1080, HepG2, Huh7, K562, primary cells, or a derivative thereof.

[0031] In some embodiments, the payload of interest is an IFN.

[0032] In some embodiments, the IFN is IFNa, IFNP, fFNy, IFNs, IFNK, IFNCO, IFN , or variants or derivatives thereof.

[0033] In some embodiments, the interferon is IFN0.

[0034] In some embodiments, a serotype of the AAV Rep and AAV Cap plasmid is derived from the group consisting of: AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV14, AAV15, AAV16, AAV-rh8, AAV-rhlO, AAV- rh20, AAV-rh39, AAV-rh74, AAV-rhM4-l, AAV-hu37, AAV-Anc80, AAV-Anc80L65, AAV- 7m8, AAV-PHP-B, AAV-PHP-EB, AAV-2.5, AAV-2tYF, AAV-3B, AAV-LK03, AAV-HSC1, AAV-HSC2, AAV-HSC3, AAV-HSC4, AAV-HSC5, AAV-HSC6, AAV-HSC7, AAV-HSC8, AAV-HSC9, AAV-HSC10, AAV-HSC11, AAV-HSC12, AAV-HSC13, AAV-HSC14, AAV- HSC15, AAV-TT, AAV-DJ / 8, AAV-Myo, AAV-NP40, AAV-NP59, AAV-NP22, AAV-NP66, AAV-HSC16, and a derivative thereof.DETAILED DESCRIPTION

[0035] Viral vectors are commonly used to deliver therapeutic genes to humans. In particular, adeno-associated viruses (AAV) have been used in recombinant viral vector systems for therapeutic delivery. Generally, rAAVs are produced using eukaryotic cells (e.g, HEK-293) via transient transfection with plasmids that provide the required components, including adenoviral helper genes, the therapeutic transgene cassette, the AAV replication machinery, and structural proteins. Expression of rAAV replication components, including viral genomes and adenovirushelper viral genes, activates numerous stress response pathways e.g., IFN signaling) that affects scalability and manufacturing of rAAVs for therapeutic applications. As such improved methods for manufacturing rAAVs comprising a payload of interest, e.g., a cytokine such as an interferon, are needed.Definitions

[0036] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the claimed subject matter belongs. Generally, nomenclatures utilized in connection with, and techniques of, immunology, oncology, cell and tissue culture, molecular biology, and protein and oligonucleotide or polynucleotide chemistry and hybridization described herein are those well-known and commonly used in the art. Units of measure not otherwise defined accord with The International System of Units (SI), NIST Special Publication 330, 2019 edition.

[0037] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of any embodiment. As used herein, the singular forms “a,” “an,” and “the” are intended to comprise the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” and / or “comprising,” when used in this specification, specify the presence of stated features, integers, steps, operations, elements, and / or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and / or groups thereof. As used herein, the term “and / or” comprises any and all combinations of one or more of the associated listed items.

[0038] As used herein, the term “adeno-associated virus vector” or “AAV vector” refers to a vector derived from an adeno-associated virus serotype, comprising without limitation, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV14, AAV15, AAV16, AAV-rh8, AAV-rhlO, AAV-rh20, AAV-rh39, AAV-rh74, AAV-rhM4-l, AAV-hu37, AAV-Anc80, AAV-Anc80L65, AAV-7m8, AAV-PHP-B, AAV- PHP-EB, AAV-2.5, AAV-2tYF, AAV-3B, AAV-LK03, AAV-HSC1, AAV-HSC2, AAV-HSC3, AAV-HSC4, AAV-HSC5, AAV-HSC6, AAV-HSC7, AAV-HSC8, AAV-HSC9, AAV-HSC10, AAV-HSC11, AAV-HSC12, AAV-HSC13, AAV-HSC14, AAV-HSC15, AAV-TT, AAV-DJ / 8, AAV-Myo, AAV-NP40, AAV-NP59, AAV-NP22, AAV-NP66, or AAV-HSC16. AAV vectorscan have one or more of the AAV wild-type genes deleted in whole or part, e.g., the Rep and / or Cap genes, but retain functional flanking inverted terminal repeat (ITR) sequences. Functional ITR sequences promote the rescue, replication, and packaging of the AAV virion. Thus, an AAV vector is defined herein to comprise at least those sequences required in cis for replication and packaging (e.g., functional ITRs) of the virus. ITRs do not need to be the wild-type nucleic acid sequences and, in some embodiments, are altered, e.g., by the insertion, deletion, or substitution of nucleotides, so long as the sequences provide for functional rescue, replication, and packaging.

[0039] Unless specifically stated or obvious from context, as used herein, the term “about” in reference to a number or range of numbers is understood to mean the stated number and numbers ±10% thereof, or 10% below the lower listed limit and 10% above the higher listed limit for the values listed for a range.

[0040] “Polynucleotide,” or “nucleic acid,” are used interchangeably herein and refer to chains of nucleotides of any length, and comprise DNA or RNA. In some embodiments, the nucleotides are deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, and / or their analogs. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and their analogs. If present, modification to the nucleotide structure is imparted before or after assembly of the chain. In some embodiments, the sequence of nucleotides is interrupted by non-nucleotide components. In some embodiments, a polynucleotide is further modified after polymerization, such as by conjugation with a labeling component. Other types of modifications comprise, for example, “caps,” substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as, for example, those with uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoamidates, carbamates) and with charged linkages (e.g., phosphorothioates, phosphorodithioates), those containing pendant moieties, such as, for example, proteins (e.g., nucleases, toxins, antibodies, signal peptides, poly-L-lysine), those with intercalators (e.g., acridine, psoralen), those containing chelators (e.g., metals, radioactive metals, boron, oxidative metals), those containing alkylators, those with modified linkages (e.g., alpha anomeric nucleic acids), as well as unmodified forms of the polynucleotide(s). In some embodiments, any of the hydroxyl groups ordinarily present in the sugars are replaced, for example, by phosphonate groups, phosphate groups, protected by standard protecting groups, or activated to prepare additional linkages to additional nucleotides,or are conjugated to solid supports. Tn some embodiments, the 5’ and 3’ terminal OH is phosphorylated or substituted with amines or organic capping group moieties of from 1 to 20 carbon atoms. Other hydroxyls may also be derivatized to standard protecting groups. In some embodiments, polynucleotides also contain analogous forms of ribose or deoxyribose sugars, comprising, for example, 2’-O-methyl-, 2’-O-allyl, 2’-fluoro- or 2’ -azido-ribose, carbocyclic sugar analogs, alpha- or beta-anomeric sugars, epimeric sugars such as arabinose, xyloses or lyxoses, pyranose sugars, furanose sugars, sedoheptuloses, acyclic analogs and abasic nucleoside analogs such as methyl riboside. In some embodiments, one or more phosphodiester linkages are replaced by alternative linking groups. These alternative linking groups comprise, but are not limited to, embodiments wherein phosphate is replaced by P(O)S(“thioate”), P(S)S (“dithioate”), (0)NRi (“amidate”), P(O)R, P(O)OR’, CO or CH2 (“formacetal”), in which each R or R’ is independently H or substituted or unsubstituted alkyl (1-20 C) optionally containing an ether (- O-) linkage, aryl, alkenyl, cycloalkyl, cycloalkenyl or araldyl. Not all linkages in a polynucleotide need be identical. The preceding description applies to all nucleic acids and polynucleotides referred to herein, comprising RNA and DNA.

[0041] A “recombinant AAV vector (rAAV vector)” refers to a nucleic acid vector derived from an AAV and comprising one or more heterologous sequences (i.e., nucleic acid sequence not of AAV origin) flanked by at least one AAV ITR. In some embodiments, such rAAV vectors are replicated and packaged into viral particles when introduced into a host cell that has a suitable helper nucleic acid or virus (or that is expressing suitable helper functions) and that expresses AAV Rep and Cap gene products (i.e. AAV Rep and Cap proteins). When a rAAV vector is incorporated into a larger nucleic acid (e.g., in a chromosome or in another vector such as a plasmid used for cloning or transfection), then the rAAV vector is referred to as a “pro-vector” which is “rescued” by replication and encapsidation in the presence of AAV packaging functions and suitable helper functions.Methods for Manufacturing rAAV Vectors

[0042] Interferons (IFNs) are grouped into three main subtypes: type I, type II, and type III. Type I IFNs including IFN bind to receptors IFNAR1 and IFNAR2. Upon interaction with IFNP the receptors dimerize and signal through a phosphorylation cascade. Receptor associated Janus tyrosine kinases (JAKs and Tyk2) are activated by transphosphorylation and subsequentlyphosphorylate and activate signal transducer and activator of transcription (STAT) proteins. Once activated, STATs dimerize and translocate into the nucleus where they bind to DNA to regulate transcription including transcription of IFN- stimulated genes. Several genes including IFNs have been shown to be increased during rAAV production leading to cytotoxicity of the production cells. As such, improved methods for manufacturing rAAV vectors are needed.

[0043] Described herein, are methods for manufacturing rAAV vectors comprising the payload of interest, the method comprising: a) providing cells with i) a transfer plasmid comprising the payload of interest; ii) a AAV Rep and AAV Cap plasmid; and iii) one or more helper nucleic acids selected from the group consisting of: Adenovirus E2, Adenovirus E4, and Adenovirus VA; and b) culturing the cells of step a) in a growth medium comprising an IFNP inhibitor or inhibitor of IFNP signaling such that the rAAV vector comprising the payload of interest is produced in the cells. In some embodiments, the cells are transfected with the transfer plasmid, the AAV Rep and AAV Cap plasmid, and / or the one or more helper nucleic acids. In some embodiments, the cells are infected with the transfer plasmid, the AAV Rep and AAV Cap plasmid, and / or the one or more helper nucleic acids.

[0044] In some embodiments, the IFN inhibitor is a nucleic acid molecule inhibitor (e.g., IFNP short interfering RNA (siRNA), IFNP microRNA (miRNA), IFNP short hairpin RNA (shRNA), IFNP antisense oligonucleotide, STAT siRNA, STAT miRNA, STAT shRNA, or STAT antisense oligonucleotide), antifungal inhibitor, small molecule inhibitor, IFNP inhibitor antibody, natural product inhibitor, or viral product inhibitor. In some embodiments, the IFNP inhibitor is a nucleic acid molecule inhibitor (e.g., IFNP short interfering RNA (siRNA), IFNP microRNA (miRNA), IFNP short hairpin RNA (shRNA), IFNP antisense oligonucleotide, STAT siRNA, STAT miRNA, STAT shRNA, and STAT antisense oligonucleotide). In some embodiments, the IFNP inhibitor is a ginsenoside (e.g., ginsenoside Rbi). In some embodiments, the IFNP inhibitor is a small molecule inhibitor (e.g., carbonyl cyanide m-chlorophenyl hydrazone (CCCP), BX795, ruxolitinib, morphine, dilaudid, methadone, MRT68844, MRT67307, Cyt387, and AZD1480). In some embodiments, the IFNP inhibitor is an IFNP inhibitor antibody (e.g., anifrolumab). In some embodiments, the IFNP inhibitor is a natural product inhibitor (e.g., emodin, aloin, capsaicin, avicin D, celastrol, withaferin A, thymoquine, caffeic acid, vinorelbine, paclitaxel, evodiamine, cryptotanshinone, honokiol, berbamine, cinnamon bark, indirubin, curcumin, FLLL11, FLLL12, FLLL2, FLLL62, resveratrol (SRT501),LTR71, piceatannol, dihydroxystilbene, tetrahydroxystilbene, hexahydroxystilbene, 2-bromo- resveratrol and 2-chloro-resveratrol, an oleanolic acid, bardoxolone, an oleanolic derivative, a 3, 5 -di substituted isoxazoles derivative, acyloxyimino derivatives, 3-acetylated derivatives, acetate, an ester derivative, oximes derivatives, catechins, and artemisinins). In some embodiments, the IFNP inhibitor is a viral product inhibitor (e.g., paramyxovirus V protein, Yaba-like disease virus Y136 protein, vaccinia virus B18 protein, Epstein-Barr virus BGLF2 protein, dengue virus NS2A protein, dengue virus NS4A protein, and dengue virus NS4B protein).

[0045] In some embodiments, the IFNP inhibitor is selected from the group consisting of: IFNP short interfering RNA (siRNA), IFNP microRNA (miRNA), IFNP short hairpin RNA (shRNA), IFNP antisense oligonucleotide, STAT siRNA, STAT miRNA, STAT shRNA, STAT antisense oligonucleotide, butoconazole nitrate, ginsenoside Rbi, carbonyl cyanide m-chlorophenyl hydrazone (CCCP), BX795, ruxolitinib, morphine, dilaudid, methadone, MRT68844, MRT67307, Cyt387, AZD1480, anifrolumab, emodin, aloin, capsaicin, avicin D, celastrol, withaferin A, thymoquine, caffeic acid, vinorelbine, paclitaxel, evodiamine, cryptotanshinone, honokiol, berbamine, cinnamon bark, indirubin, curcumin, FLLL11, FLLL12, FLLL2, FLLL62, resveratrol (SRT501), LTR71, piceatannol, dihydroxystilbene, tetrahydroxystilbene, hexahydroxystilbene, 2-bromo-resveratrol and 2-chloro-resveratrol, an oleanolic acid, bardoxolone, an oleanolic derivative, a 3,5-disubstituted isoxazoles derivative, an acyloxyimino derivative, a 3-acetylated derivative, acetate, an ester derivative, an oximes derivative, catechin, artemisinin, paramyxovirus V protein, Yaba-like disease virus Y136 protein, vaccinia virus B18 protein, Epstein-Barr virus BGLF2 protein, dengue virus NS2A protein, dengue virus NS4A protein, and dengue virus NS4B protein.

[0046] In some embodiments, the inhibitor of IFNP signaling is a JAK inhibitor. In some embodiments, the JAK inhibitor is a JAK small molecule inhibitor. In some embodiments, the JAK small molecule inhibitor is selected from the group consisting of: tofacitinib (CP690, 550 or Xeljanz), baricitinib, ruxolitinib (INCB018424 or INC424), oclacitinib, filgotinib (jyseleca), upadacitinib (ABT-494), abrocitinib (PF-04965842), itacitinib (INCB039110), fedrantinib, pacritinib, gandotinib (LY2784544), decernotinib, peficitinib (Smyraf, ASP015K, or JNJ- 54781532), momelotinib (CYT387), gusacitinib (ASN002), delgocitinib (JTE-052), cerdulatinib(PRT062070), deucravacitinib, lestauritinib, brepocitinib (PF-06700841), ivarmacitinib (SHR0302), and OST-122.

[0047] In some embodiments, the inhibitor of IFNP signaling is a STAT inhibitor In some embodiments, the STAT inhibitor is a STAT3 small molecule inhibitor. In some embodiments, the STAT3 small molecule inhibitor is selected from the group consisting of: stattic (STAT Three Inhibitory Compound), STA-21 (NSC628869), LLL-3, LLL12, XZH-5, OPB-31121, S3I- 201, inS3-54A18, STAT3-IN-1, morusin, niclosamide (BAY2353), SH-4-54, WP1066, S3I- 201.1066, S3I-1757, STX-0119, BP-1-102, OPB-11077, napabucasin (BBI608), pyrimethamine (GLG-801), TTI-101 (C188-9), nitazoxanide, and BP-5-087.

[0048] In some embodiments, the STAT inhibitor is a STAT1 small molecule inhibitor. In some embodiments, the STAT1 small molecule inhibitor is pravastatin.

[0049] In some embodiments, the STAT inhibitor is a STAT5 and / or STAT6 small molecule inhibitor. In some embodiments, the STAT5 and / or STAT6 small molecule inhibitor is a chromone-derived nicotinylhydrazone inhibitor. In some embodiments, the STAT5 and / or STAT6 small molecule inhibitor is selected from the group consisting of: pimozide, STAT5-IN- 1, AS1517499, BP-1108, BP-1075, stafia-1, leflunomide, and niflumic acid.

[0050] In some embodiments, the STAT inhibitor is a STAT peptide inhibitor or peptidomimetic inhibitor. In some embodiments, the STAT peptide inhibitor or peptidomimetic inhibitor is selected from the group consisting of: PY*LKTK (Y = phosphotyrosine), PY*LKTK and its tripeptides PY*L and AY*L, ISS610, S31-M2001, ISS840, PM-73G, CJ1383, and rPP-C8.

[0051] In some embodiments, inhibitor of IFNP signaling is a natural product inhibitor. In some embodiments, the natural product inhibitor is selected from the group consisting of: emodin, aloin, capsaicin, avicin D, celastrol, withaferin A, thymoquine, caffeic acid, vinorelbine, paclitaxel, evodiamine, cryptotanshinone, honokiol, berbamine, cinnamon bark, indirubin, curcumin, FLLL11, FLLL12, FLLL2, FLLL62, resveratrol (SRT501), LTR71, piceatannol, dihydroxystilbene, tetrahydroxystilbene, hexahydroxystilbene, 2-bromo-resveratrol and 2-chloro- resveratrol, an oleanolic acid, bardoxolone, an oleanolic derivative, a 3,5-disubstituted isoxazoles derivative, acyloxyimino derivatives, 3 -acetylated derivatives, acetate, an ester derivative, oximes derivatives, catechins, and artemisinins.

[0052] In some embodiments, inhibitor of IFNP signaling is a viral product inhibitor. In some embodiments, the viral product inhibitor is Y136 derived from Yaba-like disease virus. In someembodiments, the viral product inhibitor is Bl 8 derived from vaccinia virus. In some embodiments, the viral product inhibitor is BGLF2 derived from Epstein-Barr virus.

[0053] In some embodiments, the inhibitor of IFNP signaling is an oligodeoxynucleotide inhibitor. In some embodiments, the inhibitor of IFNP signaling inhibitor is a STAT antisense oligonucleotide, siRNA, or mRNA.

[0054] Described herein, in certain embodiments, are methods for manufacturing recombinant AAV vectors, comprising the payload of interest, the method comprising: a) providing IFNP knockdown cells with i) a transfer plasmid comprising the payload of interest; ii) a AAV Rep and AAV Cap plasmid; and iii) one or more helper nucleic acids selected from the group consisting of: Adenovirus E2, Adenovirus E4, and Adenovirus VA; and b) culturing the cells such that the rAAV vector comprising the payload of interest is produced in the cells . In some embodiments, the cells are transfected with the transfer plasmid, the AAV Rep and AAV Cap plasmid, and / or the one or more helper nucleic acids. In some embodiments, the cells are infected with the transfer plasmid, the AAV Rep and AAV Cap plasmid, and / or the one or more helper nucleic acids.

[0055] In some embodiments, generating IFNP knockdown (e.g., knockout) cells comprises the use of the clustered regularly interspaced short palindromic repeat interference (CRISPR) / Cas systems. In some embodiments, generating IFNP knockdown (e.g., knockout) cells comprises the use of the clustered regularly interspaced short palindromic repeat interference (CRISPRi) system. In CRISPRi, an engineered Cas9 protein (e.g., nuclease-null dead Cas9) can pair with a sequence specific guide RNA (sgRNA). The Cas9 gRNA complex can block RNA polymerase, thereby interfering with transcription elongation of the IFNP gene. The complex can also block transcription initiation by interfering with transcription factor binding.

[0056] In some embodiments, IFNP knockdown (e.g., knockout) cells are generated using meganucleases, zinc-finger nucleases (ZFNs), or transcription activator-like effector nuclease (TALEN). Unlike the CRISPR / Cas system, these enzymes do not contain a guiding nucleic acid to localize to a specific target sequence. Target specificity is instead controlled by DNA binding domains within these enzymes. For example, a meganuclease, ZFN, or TALEN can be targeted to introduce an indel that results in IFNP knockdown (e.g., knockout).

[0057] In some embodiments, conditional IFNP knockdown (e.g., knockout) cells are generated. In some embodiments, conditional IFNP knockdown (e.g., knockout) cells are generated in atissue specific manner. Knockout can be introduced, for example, by utilizing RNA interference, while knockout can be introduced, for example by introducing site-specific recombination sites, such as loxP sites, around the IFNp gene. Such site-specific recombination site sequences can be introduced into the germline via the same techniques as described above or known in the art. Such a germline can then be crossed to another germline containing a recombinase, for example Cre-recombinase, that can recognize these sequences, recombine the sites, and delete the IFNp gene flanked by these sites.

[0058] In some embodiments, inducible IFNP knockdown (e.g., knockout) cells are generated. In some embodiments, inducible IFN knockout cells are generated. In some embodiments, inducible IFN knockout cells are generated using a drug-inducible system (e.g., tetracycline, tamoxifen).

[0059] Various cells may be used for manufacturing rAAV vectors described herein. In some embodiments, the cell is an selected from the group consisting of A549, HEK-293, HEK-293T, BHK, CHO, HeLa, MRC5, Sf9, Cos-1, Cos-7, Vero, BSC 1, BSC 40, BMT 10, WI38, HeLa, Saos, C2C12, L cell, HT1080, HepG2, Huh7, K562, a primary cell, or derivative thereof. In some embodiments, the cell is a A549 cell or a derivative thereof. In some embodiments, the cell is a HEK-293 cell or a derivative thereof. In some embodiments, the cell is a HEK-293T cell or a derivative thereof. In some embodiments, the cell is a BHK cell or a derivative thereof. In some embodiments, the cell is a CHO cell or a derivative thereof. In some embodiments, the cell is a HeLa cell or a derivative thereof. In some embodiments, the cell is a MRC5 cell or a derivative thereof. In some embodiments, the cell is a Sf9 cell or a derivative thereof. In some embodiments, the cell is a Cos-1 cell or a derivative thereof. In some embodiments, the cell is a Cos-7 cell or a derivative thereof. In some embodiments, the cell is a Vero cell or a derivative thereof. In some embodiments, the cell is a BSC 1 cell or a derivative thereof. In some embodiments, the cell is a BSC 40 cell or a derivative thereof. In some embodiments, the cell is a BMT 10 cell or a derivative thereof. In some embodiments, the cell is a WI38 cell or a derivative thereof. In some embodiments, the cell is a HeLa cell or a derivative thereof. In some embodiments, the cell is a Saos cell or a derivative thereof. In some embodiments, the cell is a C2C12 cell or a derivative thereof. In some embodiments, the cell is a L cell or a derivative thereof. In some embodiments, the cell is a HT1080 cell or a derivative thereof. In some embodiments, the cell is a HepG2 cell or a derivative thereof. In some embodiments, the cell is aHuh7 cell or a derivative thereof. Tn some embodiments, the cell is a K562 cell or a derivative thereof. In some embodiments, the cell is a primary cell. In some embodiments, the cells are stable cell lines.

[0060] In some embodiments, the recombinant viral vectors are produced by a producer cell line method. Briefly, for example, a cell line (e.g., a HEK-293 cell line) is stably transfected with a plasmid containing a Rep gene, a Cap gene, and a promoter-payload sequence. Cell lines are screened to select a lead clone for recombinant vector production, which in some embodiments, are expanded to a production bioreactor and infected with, a helper nucleic acid (e.g., a wild-type adenovirus) as a helper to initiate vector production. In some embodiments, the recombinant viral vector (e.g., rAAV) is subsequently harvested, adenovirus is inactivated (e.g., by heat) and / or removed, and the viral particles are purified. In some embodiments, recombinant viral vectors are purified and formulated.

[0061] In some embodiments, suitable growth media is used for the production of recombinant vectors. In some embodiments, these media comprise an IFN0 inhibitor or inhibitor of IFN signaling. In some embodiments, these media comprise, without limitation, media produced by Hyclone Laboratories and JRH comprising Modified Eagle Medium (MEM), Roswell Park Memorial Institute (RPMI) 1640, Eagle’s Minimal Essential Medium (EMEM), Ham's F-10 Medium, Iscove's Modified Dulbecco's Medium (IMDM), Neuralbasal Medium, Dulbecco’s Modified Eagle Medium (DMEM), custom formulations, particularly with respect to custom media formulations for use in production of recombinant vectors.

[0062] In some embodiments, suitable production culture media of the present disclosure is supplemented with serum or serum-derived recombinant proteins at a level of 0.5-20 (v / v or w / v). In some embodiments, vectors are produced in serum-free conditions which are also referred to as media with no animal-derived products. In some embodiments, commercial or custom media is designed to support production of vectors, comprising supplementation of without limitation glucose, vitamins, amino acids, and or growth factors, in order to increase the titer and / or yield of vector in production cultures.

[0063] Vector production cultures comprise a variety of conditions (over a wide temperature range, for varying lengths of time, and the like) suitable to the particular host cell being utilized. Vector production cultures comprise attachment-dependent cultures which are cultured in suitable attachment-dependent vessels such as, for example, plates, flasks, cell stacks, rollerbottles, hollow fiber filters, microcarriers, and packed-bed or fluidized-bed bioreactors. In some embodiments, the cells are adherent.

[0064] In some embodiments, vector production cultures comprise suspension-adapted host cells such as HeLa, HEK-293, HEK-293T, HEK-293S, CHO, NSO, PER.C6, BHK, S2 and Sf9 cells which are cultured in a variety of ways comprising, for example, spinner flasks, stirred tank bioreactors, single use bioreactors such as Cytiva Xcellerex, Sartorius, and Wave, and disposable systems. In some embodiments, culturing comprises culturing the cells in a suspension culture.

[0065] In some embodiments, viral particles of the disclosure are harvested from vector production cultures by lysis of the host cells of the production culture or by harvest of the spent media from the production culture, provided the cells are cultured under conditions to cause release of viral particles into the media from intact cells. Suitable methods of lysing cells comprise for example multiple freeze / thaw cycles, sonication, microfluidization, and treatment with chemicals, such as detergents and / or proteases.

[0066] In some embodiments, the viral particles are purified. The term “purified” as used herein comprises a preparation of viral particles devoid of at least some of the other components that are present where the viral particles naturally occur or are initially prepared from. Thus, for example, in some embodiments, isolated viral particles are prepared using a purification technique to enrich it from a source mixture, such as a culture lysate or production culture supernatant. In some embodiments, enrichment is measured in a variety of ways, such as, for example, by the proportion of DNase-resistant particles (DRPs) or genome copies (gc) present in a solution, or by infectivity, or measured in relation to a second, potentially interfering substance present in the source mixture, such as contaminants and impurities, comprising product-derived and process- derived impurities and the like.

[0067] In some embodiments, the vector production culture harvest is clarified to remove host cell debris. In some embodiments, the production culture harvest is clarified by filtration through a series of depth filters comprising, for example, a grade DOHC Millipore Millistak+ HC Pod Filter, a grade A1HC Millipore Millistak+ HC Pod Filter, and a 0.2 pm Filter Opticap XL 10 Millipore Express SHC Hydrophilic Membrane filter. Clarification can also be achieved by a variety of other standard techniques, such as, centrifugation or filtration through any cellulose acetate filter of 0.2 pm or greater pore size.

[0068] In some embodiments, the vector production culture harvest is further treated with a nuclease (e.g., DNA or RNA nuclease) to digest any high molecular weight DNA present in the production culture. In some embodiments, the nuclease digestion is performed under standard conditions.

[0069] In some embodiments, viral particles are isolated or purified using one or more of the following purification steps: equilibrium centrifugation; flow-through anion exchange filtration; tangential flow filtration (TFF) for concentrating the viral particles; vector capture by apatite chromatography; heat inactivation of helper virus; vector capture by hydrophobic interaction chromatography; buffer exchange by size exclusion chromatography (SEC); nanofiltration; and vector capture by anion exchange chromatography, cation exchange chromatography, or affinity chromatography. In some embodiments, these steps are used alone, in various combinations, or in different orders. In some embodiments, the method comprises all the steps in the order as described below.

[0070] In some embodiments, the methods described herein for manufacturing a recombinant vector comprise providing cells transfected with a helper nucleic acid. In some embodiments, the cells are transfected with a helper nucleic acid that provides helper functions to the AAV. In some embodiments, the helper nucleic acid provides adenovirus functions, comprising, e.g., E1A, E1B, E2A, E4ORF6, and / or VA RNA. The sequences of adenovirus genes providing these functions, in some embodiments, are obtained from any known adenovirus serotype, such as serotypes 2, 3, 4, 5, 7, 12 and 40, and further comprising any of the presently identified human types. In some embodiments, the adenovirus functions are provided by a self-attenuating adenovirus. In some embodiments, the methods involve transfecting the cell with vectors expressing one or more genes necessary for AAV replication, AAV gene transcription, and / or AAV packaging.

[0071] In some embodiments, the methods comprise providing cells transfected with a helper nucleic acid that is under the control of a promoter. In some embodiments, the cells are stable host cells comprising the required component(s) under the control of an inducible promoter. In some embodiments, the cells are stable host cells comprising the required component(s) under the control of a constitutive promoter. In some embodiments, the cells are stable host cells comprising the selected components under the control of a constitutive promoter and other selected components under the control of one or more inducible promoters. For example, a stablehost cell is generated which is derived from HEK-293 cells (which contain El helper functions under the control of a constitutive promoter), but which contains the Rep and / or Cap proteins under the control of inducible promoters. In some embodiments, the promoter is selected from the group consisting of: CMV, CBA, EFla, CAG, PGK, TRE, U6, UAS, T7, Sp6, lac, araBad, trp, Ptac, p5, pl9, p40, Synapsin, GFAP, CaMKII, GRK1, and derivatives thereof.

[0072] In some embodiments, the nucleic acid comprising the payload of interest and / or the components for rAAV production are delivered to the cells in a form of any genetic element which transfers the sequences. In some embodiments, the selected genetic elements are delivered by any suitable method including by transfection or infection of the cells.

[0073] Production of recombinant vectors, such as rAAV vectors, in some embodiments, comprises transfection, stable cell line production, and infectious hybrid virus production systems which comprise adenovirus- AAV hybrids, herpesvirus- AAV hybrids, bocavirus-AAV hybrids, and baculovirus-AAV hybrids.

[0074] In some embodiments, rAAV production cultures for the production of rAAV virus particles comprise suitable host cells (e.g., HeLa, A549, or HEK-293 cells, or HEK-293T cells, or HEK-293S cells, or insect-derived cell lines such as Sf9, in the case of baculovirus production systems, or transgenic plant cells); suitable helper virus function provided by wild-type or mutant adenovirus (such as temperature-sensitive adenovirus), herpes virus, baculovirus, or a plasmid construct providing helper functions; AAV Rep and Cap genes and gene products; a payload of interest (such as a heterologous sequence encoding any desired sequence or fragment or variant thereof) flanked by at least one AAV ITR sequence; suitable growth media comprising an IFN0 inhibitor or inhibitor of IFNP signaling and media components to support rAAV production, or combinations thereof. Suitable media for the production of rAAV vectors comprise, without limitation, media produced by Hyclone Laboratories and JRH comprising Modified Eagle Medium (MEM), Roswell Park Memorial Institute (RPMI) 1640, Eagle’s Minimal Essential Medium (EMEM), Ham's F-10 Medium, Iscove's Modified Dulbecco's Medium (EMDM), Neuralbasal Medium, Dulbecco’s Modified Eagle Medium (DMEM).

[0075] In some embodiments, recombinant AAV vectors are generated by transfecting producer cells with a plasmid (cis plasmid, i.e., transfer plasmid) containing a rAAV genome comprising a payload flanked by one or more AAV ITRs and a separate construct expressing the AAV Rep and Cap genes in trans (i.e., AAV Rep and AAV Cap plasmid). In some embodiments,adenovirus helper nucleic acids such as El A, E1B, E2A, E4ORF6 and VA RNAs are provided by either adenovirus infection or by transfecting a third plasmid providing adenovirus helper nucleic acids into the producer cells. In some embodiments, producer cells are HEK-293 cells. In some embodiments, the helper nucleic acids provided will vary depending on the producer cells used and whether the producer cells already carry some of these helper nucleic acids.

[0076] In some embodiments, the rAAV vectors described herein are produced by a triple transfection method, such as the exemplary triple transfection method provided infra. In some embodiments, the plasmid containing a Rep gene and a Cap gene, along with a helper adenoviral plasmid, is transfected (e.g., using squeeze-poration, lipofection, optical transfection, the calcium phosphate method, or polyethylenimine (PEI)) into a cell line (e.g., HEK-293 cells), and virus is collected and optionally purified.

[0077] In some embodiments, rAAV vectors are produced by a producer cell line method, such as the exemplary producer cell line method provided infra. Briefly, a cell line (e.g., a HEK-293 cell line) is stably transfected with a plasmid containing a Rep gene, a Cap gene, and a promoterpayload sequence. Cell lines are screened to select a lead clone for rAAV production, which are then expanded to a production bioreactor and infected with an adenovirus (e.g., a wild-type adenovirus) as helper to initiate rAAV production. Virus is subsequently harvested, adenovirus may be inactivated (e.g., by heat) and / or removed, and the rAAV vectors are purified.

[0078] In some embodiments, methods are provided for manufacturing rAAV vectors disclosed herein comprising (a) culturing a host cell under a condition that rAAV vectors are produced, wherein the host cell comprises (i) one or more AAV packaging genes, wherein each said AAV packaging gene encodes an AAV replication and / or encapsidation protein; (ii) a rAAV provector comprising nucleic acids encoding a therapeutic polypeptide and / or nucleic acid as described herein flanked by at least one AAV ITR, and (iii) an AAV helper function; and (b) recovering the rAAV vectors produced by the host cell. In some embodiments, the at least one AAV ITR is selected from the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV 10, AAV11, AAV 12, AAV13, AAV 14, AAV15, AAV 16, AAV-rh8, AAV-rhlO, AAV-rh20, AAV-rh39, AAV-rh74, AAV-rhM4-l, AAV-hu37, AAV- Anc80, AAV-Anc80L65, AAV-7m8, AAV-PHP-B, AAV-PHP-EB, AAV-2.5, AAV-2tYF, AAV-3B, AAV-LK03, AAV-HSC1, AAV-HSC2, AAV-HSC3, AAV-HSC4, AAV-HSC5, AAV-HSC6, AAV-HSC7, AAV-HSC8, AAV-HSC9, AAV-HSC10, AAV-HSC11, AAV-HSC12, AAV-HSC13, AAV-HSC14, AAV-HSC15, AAV-TT, AAV-DJ / 8, AAV-Myo, AAV- NP40, AAV-NP59, AAV-NP22, AAV-NP66, AAV-HSC16, a goat AAV, bovine AAV, or mouse AAV or the like.

[0079] In some embodiments, the payload of interest is interferon.

[0080] In some embodiments, the payload of interest is IFNa, IFN0, IFNy, IFNs, IFNK, IFNOJ, IFN , or variants or derivatives thereof. In some embodiments, the interferon is IFNa or a variant or derivative thereof. In some embodiments, the interferon is IFN0 or a variant or derivative thereof. In some embodiments, the interferon is IFNy or a variant or derivative thereof. In some embodiments, the interferon is IFNs or a variant or derivative thereof. In some embodiments, the interferon is IFNK or a variant or derivative thereof. In some embodiments, the interferon is IFNco or a variant or derivative thereof. In some embodiments, the interferon is IFNX or a variant or derivative thereof.

[0081] In some embodiments, the rAAV is derived from the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV14, AAV15, AAV16, AAV-rh8, AAV-rhlO, AAV-rh20, AAV-rh39, AAV-rh74, AAV- rhM4-l, AAV-hu37, AAV-Anc80, AAV-Anc80L65, AAV-7m8, AAV-PHP-B, AAV-PHP-EB, AAV-2.5, AAV-2tYF, AAV-3B, AAV-LK03, AAV-HSC1, AAV-HSC2, AAV-HSC3, AAV- HSC4, AAV-HSC5, AAV-HSC6, AAV-HSC7, AAV-HSC8, AAV-HSC9, AAV-HSC10, AAV- HSC11, AAV-HSC12, AAV-HSC13, AAV-HSC14, AAV-HSC15, AAV-TT, AAV-DJ / 8, AAV- Myo, AAV-NP40, AAV-NP59, AAV-NP22, AAV-NP66, or AAV-HSC16, or a derivative thereof.EXAMPLES

[0082] Below are examples of specific embodiments for carrying out the present disclosure. The examples are offered for illustrative purposes only and are not intended to limit the scope of the present disclosure in any way. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should, of course, be allowed for.Example 1. Manufacturing a Recombinant AAV with a growth medium comprising an IFNp inhibitor or inhibitor of IFN|J signaling

[0083] An exemplary workflow for manufacturing engineered recombinant AAV (rAAV) vectors is described in the following.

[0084] To generate a rAAV, cells (e.g., HEK-293 cells or A549 cells) are transfected with a nucleic acid comprising a payload of interest (e.g., IFNP). Along with the nucleic acid comprising the payload of interest, the cells are stably transfected with one or more plasmids containing an AAV Rep gene, an AAV Cap gene, Adenovirus E2 gene, Adenovirus E4 gene, Adenovirus VA gene, and a promoter-payload sequence. Following transfection, the cells are cultured in a growth medium comprising an IFNP inhibitor, such as BX795, or an inhibitor of IFNP signaling. The cell are subsequently screened to select a lead clone expressing the payload of interest for recombinant vector production, which is then expanded to a production bioreactor and infected with, a helper nucleic acid (e.g., a wild-type adenovirus) as a helper to initiate vector production. The rAAV is subsequently harvested by lysis of the host cells, the adenovirus is inactivated (e.g., by heat), and the viral particles are purified using, for example, equilibrium centrifugation, followed by clarification, with, for example, a grade DOHC Millipore Millistak+ HC Pod Filter, to remove host cell debris. The vector production culture harvest is also treated with a nuclease to digest any high molecular weight DNA present in the production culture.Example 2. Manufacturing a Recombinant AAV with IFNP Knockout Cells

[0085] An exemplary workflow for manufacturing engineered recombinant AAV (rAAV) vectors is described in the following.

[0086] IFNP knockout cells are generated, for example, through the use of a site-specific recombination system. For example, loxP sites are inserted into the genomic DNA at sites flanking the IFNP gene. Cre recombinase is introduced into the cells and the IFNP gene is deleted, thereby generating IFNP knockout cells. Such cells are then transfected with a nucleic acid comprising a payload of interest (e.g., IFNP). One of skill in the art will understand that knockdown can alternatively used. Along with the nucleic acid comprising the payload of interest, the cells are stably transfected with a plasmid containing an AAV Rep gene, an AAV Cap gene, Adenovirus E2 gene, Adenovirus E4 gene, Adenovirus VA gene, and a promoterpayload sequence. Following transfection, the cells are cultured in a growth medium. The cell are subsequently screened to select a lead clone expressing the payload of interest for recombinant vector production, which is then expanded to a production bioreactor and infectedwith, a helper nucleic acid (e.g., a wild-type adenovirus) as a helper to initiate vector production. The rAAV is subsequently harvested by lysis of the host cells, the adenovirus is inactivated (e.g., by heat), and the viral particles are purified using, for example, equilibrium centrifugation, followed by clarification, with, for example, a grade DOHC Millipore Millistak+ HC Pod Filter, to remove host cell debris. The vector production culture harvest is also treated with a nuclease to digest any high molecular weight DNA present in the production culture.

Claims

CLAIMS1. A method for manufacturing a recombinant adeno-associated virus (rAAV) vector comprising a payload of interest, the method comprising: a) providing cells with i) a transfer plasmid comprising the payload of interest; ii) a AAV Rep and AAV Cap plasmid; and iii) one or more helper nucleic acids selected from the group consisting of: Adenovirus E2, Adenovirus E4, and Adenovirus VA; and b) culturing the cells of step a) in a growth medium comprising an IFNP inhibitor or inhibitor of IFNP signaling such that the rAAV vector comprising the payload of interest is produced in the cells.

2. The method of claim 1, wherein step a) comprises transfecting the cells with the transfer plasmid, the AAV Rep and AAV Cap plasmid, and / or the one or more helper nucleic acids.

3. The method of claim 1, wherein step a) comprises transducing or infecting the cells with the transfer plasmid, the AAV Rep and AAV Cap plasmid, and / or the one or more helper nucleic acids.

4. The method of any one of claims 1-3, wherein the IFNP inhibitor is a nucleic acid molecule, small molecule, IFNP antibody, or natural product.

5. The method of claim 4, wherein the nucleic acid molecule is selected from the group consisting of: IFNP short interfering RNA (siRNA), IFNP microRNA (miRNA), IFNP short hairpin RNA (shRNA), IFNP antisense oligonucleotide, STAT siRNA, STAT miRNA, STAT shRNA, and STAT antisense oligonucleotide.

6. The method of claim 4, wherein the small molecule is selected from the group consisting of: carbonyl cyanide m-chlorophenyl hydrazone (CCCP), BX795, ruxolitinib, morphine, dilaudid, methadone, MRT68844, MRT67307, Cyt387, and AZD1480.

7. The method of claim 4, wherein the IFNP antibody is anifrolumab.

8. The method of claim 4, wherein the natural product is selected from the group consisting of: emodin, aloin, capsaicin, avicin D, celastrol, withaferin A, thymoquine, caffeic acid, vinorelbine, paclitaxel, evodiamine, cryptotanshinone, honokiol, berbamine, cinnamon bark or a small molecule therein, indirubin, curcumin, FLLL11, FLLL12, FLLL2, FLLL62, resveratrol (SRT501), LTR71, piceatannol, dihydroxystilbene, tetrahydroxystilbene, hexahydroxystilbene, 2- bromo-resveratrol and 2-chloro-resveratrol, an oleanolic acid, bardoxolone, an oleanolic derivative, a 3, 5 -di substituted isoxazoles derivative, an acyloxyimino derivative, a 3-acetylatedderivative, acetate, an ester derivative, an oximes derivative, catechin, artemisinin, paramyxovirus V protein, Yaba-like disease virus Y136 protein, vaccinia virus B18 protein, Epstein-Barr virus BGLF2 protein, dengue virus NS2A protein, dengue virus NS4A protein, and dengue virus NS4B protein.

9. The method of any one of claims 1-4, wherein the inhibitor of IFNP signaling is a JAK inhibitor.

10. The method of claim 9, wherein the JAK inhibitor is a small molecule inhibitor.

11. The method of claim 9, wherein the JAK inhibitor is selected from the group consisting of: tofacitinib (CP690, 550 or Xeljanz), baricitinib, ruxolitinib (INCB018424 or INC424), oclacitinib, fdgotinib (jyseleca), upadacitinib (ABT-494), abrocitinib (PF-04965842), itacitinib (INCB039110), fedrantinib, pacritinib, gandotinib (LY2784544), decernotinib, peficitinib (Smyraf, ASP015K, or JNJ-54781532), momelotinib (CYT387), gusacitinib (ASN002), delgocitinib (JTE-052), cerdulatinib (PRT062070), deucravacitinib, lestauritinib, brepocitinib (PF-06700841), ivarmacitinib (SHR0302), and OST-122.

12. The method of any one of claims 1-4, wherein the inhibitor of IFNP signaling is a STAT inhibitor.

13. The method of claim 12, wherein the STAT inhibitor is a small molecule inhibitor, peptide inhibitor, or peptidomimetic inhibitor.

14. The method of claim 12, wherein the STAT inhibitor is selected from the group consisting of: stattic (STAT Three Inhibitory Compound), STA-21 (NSC628869), LLL-3, LLL12, XZH-5, OPB-31121, S3I-201, inS3-54A18, STAT3-IN-1, morusin, niclosamide (BAY2353), SH-4-54, WP1066, S3I-201.1066, S3I-1757, STX-0119, BP-1-102, OPB-11077, napabucasin (BBI608), pyrimethamine (GLG-801), TTI-101 (C188-9), nitazoxanide, BP-5-087, pravastatin, pimozide, STAT5-IN-1, AS1517499, BP-1108, BP-1075, stafia-1, leflunomide, niflumic acid, PY*LKTK (Y = phosphotyrosine), PY*LKTK and its tripeptides PY*L and AY*L, ISS610, S31-M2001, ISS840, PM-73G, CJ1383, and rPP-C8.

15. The method of any one of claims 1-14, wherein step b) comprises culturing the cells in a suspension culture.

16. The method of any one of claims 1-14, wherein step b) comprising culturing the cells in an adherent culture.

17. The method of any one of claims 1-14, wherein the cells are stable cell lines.

18. The method of any one of claims 1-17, wherein the cells are selected from the group consisting of: A549, HEK-293, HEK-293T, BHK, CHO, HeLa, MRC5, Sf9, Cos-1, Cos-7, Vero, BSC 1, BSC 40, BMT 10, WI38, HeLa, Saos, C2C12, L cell, HT1080, HepG2, Huh7, K562, primary cells, and a derivative thereof.

19. The method of any one of claims 1-18, wherein the payload of interest is an interferon (IFN).

20. The method of claim 19, wherein the interferon is IFN alpha (IFNa), IFN beta (IFNP), IFN gamma (FFNy), IFN epsilon (IFNe), IFN kappa (IFNK), IFN omega (IFNw), IFN lambda (IF NX), or variants or derivatives thereof.

21. The method of claim 20, wherein the interferon is IFNp.

22. The method of any one of claims 1-21, wherein a serotype of the AAV Rep and AAV Cap plasmid is derived from the group consisting of: AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV 10, AAV11, AAV 12, AAV13, AAV 14, AAV15, AAV 16, AAV-rh8, AAV-rhlO, AAV-rh20, AAV-rh39, AAV-rh74, AAV-rhM4-l, AAV-hu37, AAV- Anc80, AAV-Anc80L65, AAV-7m8, AAV-PHP-B, AAV-PHP-EB, AAV-2.5, AAV-2tYF, AAV-3B, AAV-LK03, AAV-HSC1, AAV-HSC2, AAV-HSC3, AAV-HSC4, AAV-HSC5, AAV-HSC6, AAV-HSC7, AAV-HSC8, AAV-HSC9, AAV-HSC10, AAV-HSC11, AAV- HSC12, AAV-HSC13, AAV-HSC14, AAV-HSC15, AAV-TT, AAV-DJ / 8, AAV-Myo, AAV- NP40, AAV-NP59, AAV-NP22, AAV-NP66, AAV-HSC16, and a derivative thereof.

23. A method for manufacturing a recombinant adeno-associated virus AAV (rAAV) vector, comprising the payload of interest, the method comprising: a) providing IFNP knockdown cells with i) a transfer plasmid comprising the payload of interest; ii) a AAV Rep and AAV Cap plasmid; and iii) one or more helper nucleic acids selected from the group consisting of: Adenovirus E2, Adenovirus E4, and Adenovirus VA; and b) culturing the cells such that the rAAV vector comprising the payload of interest is produced in the cells .

24. The method of claim 23, wherein step a) comprises transfecting the cells with the transfer plasmid, the AAV Rep and AAV Cap plasmid, and / or the one or more helper nucleic acids.

25. The method of claim 23, wherein step a) comprises transducing or infecting the cells with the transfer plasmid, the AAV Rep and AAV Cap plasmid, and / or the one or more helper nucleic acids.

26. The method of any one of claims 23-25, wherein step b) comprises culturing the cells in a suspension culture.

27. The method of any one of claims 23-25, wherein step b) comprising culturing the cells in an adherent culture.

28. The method of any one of claims 23-27, wherein the cells are from a stable cell line.

29. The method of any one of claims 23-28, wherein the cells are selected from the group consisting of: A549, HEK-293, HEK-293T, BHK, CHO, HeLa, MRC5, Sf9, Cos-1, Cos-7, Vero, BSC 1, BSC 40, BMT 10, WI38, HeLa, Saos, C2C12, L cell, HT1080, HepG2, Huh7, K562, primary cells, or a derivative thereof.

30. The method of any one of claims 23-29, wherein the payload of interest is an IFN.

31. The method of claim 30, wherein the IFN is IFNa, IFNp, IFNy, IFNs, IFNK, IFNCO, IFN , or variants or derivatives thereof.

32. The method of claim 31, wherein the interferon is IFNp.

33. The method of any one of claims 23-32, wherein a serotype of the AAV Rep and AAV Cap plasmid is derived from the group consisting of: AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV 10, AAV11, AAV 12, AAV13, AAV 14, AAV15, AAV 16, AAV-rh8, AAV-rhlO, AAV-rh20, AAV-rh39, AAV-rh74, AAV-rhM4-l, AAV-hu37, AAV- Anc80, AAV-Anc80L65, AAV-7m8, AAV-PHP-B, AAV-PHP-EB, AAV-2.5, AAV-2tYF, AAV-3B, AAV-LK03, AAV-HSC1, AAV-HSC2, AAV-HSC3, AAV-HSC4, AAV-HSC5, AAV-HSC6, AAV-HSC7, AAV-HSC8, AAV-HSC9, AAV-HSC10, AAV-HSC11, AAV- HSC12, AAV-HSC13, AAV-HSC14, AAV-HSC15, AAV-TT, AAV-DJ / 8, AAV-Myo, AAV- NP40, AAV-NP59, AAV-NP22, AAV-NP66, AAV-HSC16, and a derivative thereof.

Citation Information

Patent Citations

  • Gene therapy for immuno-oncology applications

    WO2022006332A2

Cited By

  • Method for improving virus packaging yield or quality in cells

    WO2025180499A1